Wilson Sonsini Goodrich & Rosati advised Alpine Immune Sciences on the offering, and Latham & Watkins advised the underwriters. Alpine Immune Sciences, Inc. (Nasdaq: ALPN) announced the...
Alpine Immune Sciences’ $150 Million Common Stock Offering
Vistagen’s US$100 Million Underwritten Offering
Latham & Watkins LLP represents Vistagen in the offering. Vistagen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for...
Boston Scientific’s $850 Million Acquisition of Relievant MedSystems
Faegre Drinker advised Boston Scientific, and Latham & Watkins advised Relievant MedSystems on the deal. Boston Scientific Corporation (NYSE: BSX) announced it has entered into a...
Neumora Therapeutics’ $250.1 Million Initial Public Offering
Latham & Watkins advised Neumora, and Cooley advised the underwriters. Neumora Therapeutics, Inc. announced the pricing of its initial public offering of 14,710,000 shares of its common...
Gilead’s $2 Billion Senior Unsecured Notes Offering
Davis Polk advised Gilead, and Latham & Watkins advised the underwriters. Gilead Sciences, Inc. (Nasdaq: GILD) announced the pricing of senior unsecured notes in an aggregate...
Thoma Bravo’s Acquisition of NextGen Healthcare
Latham & Watkins advised NextGen Healthcare, Goodwin Procter advised Thoma Bravo, and Skadden advised Morgan Stanley & Co. LLC as financial advisor to NextGen Healthcare on...
VBA’s US$156 Million Growth Funding From Spectrum Equity
Latham & Watkins advises Spectrum Equity in US$156 million growth funding for VBA. VBA, a leader in cloud-based benefits software for healthcare payers, has announced that...
MindMed’s Senior Secured Credit Facility With K2 HealthVentures LLC
Latham & Watkins advises MindMed in growth financing with K2 HealthVentures. Mind Medicine Inc. (MindMed), a clinical stage biopharmaceutical company developing novel product candidates to treat...
Heron Therapeutics’ Capital Credit Facility Agreement With Hercules Capital
Latham & Watkins advises on Heron Therapeutics’ working capital credit facility. Heron Therapeutics, Inc. (Heron), a commercial-stage biotechnology company focused on improving the lives of patients...
Ikena Oncology’s Acquisition of Pionyr Immunotherapeutics
Latham & Watkins advised Pionyr on the sale. Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena) and Pionyr Immunotherapeutics, Inc. have announced the closing of Ikena’s acquisition of...
PROCEPT BioRobotics’ $172.5 Million Common Stock Offering
Latham & Watkins advised PROCEPT BioRobotics, and Shearman & Sterling advised the underwriters. PROCEPT BioRobotics Corporation announced a follow-on offering of 5,085,494 shares of common stock at...
Revolution Medicines’ Acquisition of EQRx
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...